Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves first new weight loss drug in 13 years

June 28, 2012

New fusion proteins for bone disorders designed in Korea

June 28, 2012

Amicus reports preliminary results from phase II study in Pompe's disease

June 28, 2012

Lilly diabetes drug substantially decreases HbA1c without delaying recovery from hypoglycemia

June 28, 2012

Novo Nordisk presents new long-acting drug for growth hormone deficiency

June 28, 2012

Phase III study planned for MOD-4023

June 28, 2012

New acetyl-CoA carboxylase inhibitors prepared in Japan

June 27, 2012

Lexicon discloses phase IIb data on LX-4211

June 26, 2012

Novel FFA1 receptor agonists disclosed by Boehringer Ingelheim

June 26, 2012

New safety data from SMART trials disclosed at ongoing conference

June 26, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...